- Home
- AEI vs IMRN Comparison
AEI vs IMRN Comparison
Compare AEI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- IMRN
- Stock Information
- Founded
- AEI 2014
- IMRN 1994
- Country
- AEI United States
- IMRN Australia
- Employees
- AEI N/A
- IMRN N/A
- Industry
- AEI Building operators
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AEI Real Estate
- IMRN Health Care
- Exchange
- AEI Nasdaq
- IMRN Nasdaq
- Market Cap
- AEI 9.5M
- IMRN 9.2M
- IPO Year
- AEI N/A
- IMRN N/A
- Fundamental
- Price
- AEI $0.96
- IMRN $1.88
- Analyst Decision
- AEI
- IMRN Strong Buy
- Analyst Count
- AEI 0
- IMRN 1
- Target Price
- AEI N/A
- IMRN $5.00
- AVG Volume (30 Days)
- AEI 52.5K
- IMRN 25.2K
- Earning Date
- AEI 08-12-2025
- IMRN 07-07-2025
- Dividend Yield
- AEI N/A
- IMRN N/A
- EPS Growth
- AEI N/A
- IMRN N/A
- EPS
- AEI N/A
- IMRN N/A
- Revenue
- AEI $16,097,995.00
- IMRN $4,048,286.00
- Revenue This Year
- AEI N/A
- IMRN N/A
- Revenue Next Year
- AEI N/A
- IMRN N/A
- P/E Ratio
- AEI N/A
- IMRN N/A
- Revenue Growth
- AEI N/A
- IMRN 82.90
- 52 Week Low
- AEI $0.70
- IMRN $1.50
- 52 Week High
- AEI $2.61
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- AEI 57.66
- IMRN 58.70
- Support Level
- AEI $0.93
- IMRN $1.68
- Resistance Level
- AEI $1.01
- IMRN $1.94
- Average True Range (ATR)
- AEI 0.07
- IMRN 0.09
- MACD
- AEI 0.01
- IMRN 0.02
- Stochastic Oscillator
- AEI 67.85
- IMRN 76.92
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.